
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

39256432
71971
10.1038/s41598-024-71971-6
Article
Significance of changes in cavity after treatment in Mycobacterium avium complex pulmonary disease
Kim Joong-Yub 12
Bae Juye 1
Hyung Kwonhyung 1
Lee Inhan 1
Park Hyun-Jun 1
Kim So Yeon 1
Lee Kyung-Eui 35
Ahn Yoon Hae 3
Yoon Si Mong 4
Kwak Nakwon 12
Yim Jae-Joon yimjj@snu.ac.kr

12
1 grid.412484.f 0000 0001 0302 820X Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea
2 https://ror.org/04h9pn542 grid.31501.36 0000 0004 0470 5905 Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
3 https://ror.org/01z4nnt86 grid.412484.f 0000 0001 0302 820X Department of Critical Care Medicine, Seoul National University Hospital, Seoul, Republic of Korea
4 https://ror.org/00cb3km46 grid.412480.b 0000 0004 0647 3378 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
5 https://ror.org/01r024a98 grid.254224.7 0000 0001 0789 9563 Present Address: Department of Pulmonology, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, Republic of Korea
10 9 2024
10 9 2024
2024
14 211338 4 2024
2 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Cavities are characteristic radiological features related to increased mycobacterial burden and poor prognosis in Mycobacterium avium complex pulmonary disease (MAC-PD). However, cavity changes following treatment and their clinical implications remain unknown. We aimed to elucidate whether cavity obliteration or reduction in cavity size or wall thickness correlates with microbiological cure. In total, 136 adult patients with cavitary MAC-PD treated for ≥ 6 months between January 1st, 2009, and December 31st, 2021, in a tertiary referral centre in South Korea were enrolled. The cavity with the largest diameter at treatment initiation was tracked for size and thickness changes. Following median treatment of 20.0 months, 74 (54.4%) patients achieved microbiological cure. Cavity obliteration, achieved in 58 (42.6%) patients at treatment completion, was independently associated with microbiological cure. In patients with persistent cavities, size reduction of ≥ 10% was significantly associated with microbiological cure, whereas thickness reduction was not. Five-year mortality rates in patients with cavity obliteration, persistent but reduced cavity, and persistent cavity without shrinkage were 95.6%, 72.1%, and 65.3%, respectively (P < 0.001). In conclusion, cavity obliteration or shrinkage at treatment completion is associated with microbiological cure and reduced mortality in MAC-PD, suggesting that cavity changes could serve as a proxy indicator for treatment response.

Keywords

Nontuberculous mycobacteria
Cavity
Radiology
Microbiological cure
Mortality
Subject terms

Medical research
Respiratory signs and symptoms
issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Nontuberculous mycobacterial pulmonary disease (NTM-PD) is a chronic lung condition caused by mycobacteria other than Mycobacterium tuberculosis complex and Mycobacterium leprae1,2. After exclusion of other pulmonary diseases, diagnosis is established when patients exhibit pulmonary or systemic symptoms together with radiological features consistent with NTM-PD, as well as multiple positive NTM cultures from respiratory specimens1,2. NTM-PD can be classified into three clinical phenotypes: fibrocavitary, cavitary nodular bronchiectatic, and non-cavitary nodular bronchiectatic3. As implied by their names, the presence of cavitary changes is a characteristic radiological feature associated with disease progression and an unfavourable prognosis in patients with NTM-PD4.

Cavities are abnormal air-filled spaces that replace the normal lung parenchyma and are surrounded by inflammatory cells and fibrosis5–7. A concerted effort by macrophages, lymphocytes, and multinucleated giant cells to sequester mycobacteria and inhibit their spread results in the formation of granulomas6. The hypoxic and nutrient-deprived environment within these granulomas induces central necrosis, and subsequent expulsion of caseous necrotic materials into nearby bronchial trees leads to the development of cavities8. The presence of cavity is frequently associated with men, heavy smokers, patients with alcohol use disorder, and immunocompromised hosts with disturbed cell-mediated immunity9–11.

Patients with cavities observed on chest computed tomography (CT) are approximately five times more likely to experience disease progression necessitating antimycobacterial treatment12. Moreover, presence of cavities has consistently been associated with diminished health-related quality of life and increased mortality13,14. Consequently, current international treatment guidelines suggest initiating treatment in patients with cavitary lung disease rather than adopting a watchful waiting approach, after careful consideration of comorbidities, infecting species, patient priorities, and discussing the potential adverse effects and uncertain benefits of antibiotic therapy1.

Meanwhile, the changes in cavitary lesions following treatment and their clinical implications are largely unknown. The frequency of cavitary obliteration or reduction in size and wall thickness after treatment, as well as the impacts of these changes on the clinical outcomes of patients, remain unclear. The present study aimed to investigate the changes in cavitary lesions after treatment and clarify their relationships with treatment outcomes and long-term survival in patients with Mycobacterium avium complex pulmonary disease (MAC-PD), the most common form of NTM-PD.

Methods

Ethics statement

The study was approved and the requirement for informed consent was waived by the Institutional Review Board of Seoul National University Hospital (approval number: H-2311-030-14836) due to the retrospective nature of the study design. The study was performed in accordance with the principles of the Declaration of Helsinki.

Study population

We analysed consecutive patients treated for MAC-PD between January 1st, 2009 and December 31st, 2021 at a tertiary referral centre in South Korea. The following inclusion criteria were applied: (a) age ≥ 19 years, (b) satisfying the diagnostic criteria for NTM-PD1,2, (c) identification of MAC species by molecular methods15, (d) receipt of guideline-based therapy with a macrolide in combination with one or more of ethambutol, rifampicin, amikacin or streptomycin, and clofazimine for ≥ 6 months, and (e) confirmed presence of ≥ 1 cavitary changes annotated by a radiologist on a chest CT scan at initiation of treatment. The exclusion criteria were absence of chest CT scans at the start and end of treatment within a window period of 4 months, and performance of acid-fast bacilli (AFB) cultures fewer than three times during the treatment period, hindering assessment of the treatment response. Our study included patients whose cavitary lesions were diagnosed by their attending physicians as attributable to MAC-PD and not to other causes, including tuberculosis, fungal infections, or malignancies. Cases where alternative aetiologies were identified were excluded. We also included patients with antibiotic resistance, including resistance to macrolides. Some patients from our previous studies were included16–19.

Data collection, follow-up, and outcome definition

We retrospectively collected demographic, clinical, bacteriological, and laboratory data including age, sex, body mass index (BMI), erythrocyte sedimentation rate, AFB smear positivity, mycobacterial culture results, causative species, macrolide resistance, comorbidities, smoking history, antibiotics usage, treatment duration, and performance of surgical resection. Patients undergoing treatment were followed up every 1–3 months. At each visit, sputum was collected for AFB smear analysis and mycobacterial culture, and chest radiographs, complete blood counts, and hepatic and renal function tests were performed. Chest CT scans were obtained at 6–12 months following treatment initiation. The primary outcome, microbiological cure, was defined as having ≥ 3 consecutive negative cultures collected ≥ 4 weeks apart20 and maintaining negative cultures until completion of treatment17. The secondary outcome was all-cause mortality. Data on survival status and date of death were obtained from a database verified by the Ministry of the Interior and Safety, South Korea.

Evaluation of cavity characteristics

We analysed chest CT scans using a picture archiving and communication system with a preset CT assessment protocol21–23. After an educational and Q&A session prior to data collection, a group of board-certified pulmonologists blinded to treatment outcomes obtained information regarding the number, lobar distribution, and bilateral occurrence of cavities on chest CT scans at treatment initiation and completion. The left upper and lingular divisions were counted as distinct lobes23. The cavity with the largest diameter was tracked for changes in size and wall thickness. The maximum transverse diameter, determined by measuring the longest outer diameter including wall thickness on axial images with a slice thickness of 1.00 or 1.25 mm served as the cavity size22. The greatest wall thickness on the CT section where the transverse diameter was measured was noted as the wall thickness21. Uncertainties in measurement were resolved after consultation with the first and corresponding authors. Cavity obliteration was defined as closure or healing of cavities resulting in the absence of abnormal air-filled spaces, and usually transforming into a fibrous scar or nodule (Fig. 1)24. Patients who underwent complete surgical resection of cavities leading to absence of residual lesions were also considered to have achieved cavity obliteration and were included in this study to provide a more comprehensive view of current treatment options and outcomes.Fig. 1 Examples of cavity obliteration. Serial chest computed tomography (CT) scans of patients who achieved cavity obliteration following treatment. (A) Baseline CT scan of a woman in her seventies infected with Mycobacterium intracellulare reveals a cavity in her right lower lobe. After 18 months of antibiotic treatment, her cavity was obliterated and transformed into a nodular lesion, and she achieved microbiological cure. (B) Despite treatment with antibiotics for almost 3 years, a woman in her sixties infected with M. intracellulare had persistently positive mycobacterial cultures with minimal radiological improvement. She underwent video-assisted thoracoscopic surgery to remove the lingular division, the left lower lobe superior segment, and parts of the left lower lobe postero- and latero-basal segments. She continued antibiotic treatment for another 18 months after surgery and achieved microbiological cure.

Statistical analysis

Demographic and clinical characteristics at treatment initiation were compared between patients who achieved microbiological cure and those who did not. Categorical variables were presented as frequency with proportion and compared using Pearson’s χ2 test or Fisher’s exact test as indicated. Non-parametric continuous variables were presented as median with interquartile range (IQR) and compared using the Mann–Whitney U test.

We conducted logistic regression analysis to investigate the association between cavity obliteration at the end of treatment and microbiological cure in the entire study cohort. Subsequently, we analysed the associations between changes in size or wall thickness and microbiological cure among patients with persistent cavities. We employed three methods to examine the association between changes in size or wall thickness and microbiological cure. First, we explored the relationship between changes in size or wall thickness and microbiological cure as continuous variables. Second, we determined the minimal clinically important difference (MCID) and assessed changes in microbiological cure for reductions surpassing the MCID. The MCID was calculated by the receiver operating characteristic (ROC) method using microbiological cure as an anchor and the standard error of measurement (SEM) method for a distribution-based approach25,26, and the final MCID was determined by selecting the smaller of the two values. Third, we examined the association between a specific percentage reduction or increase and microbiological cure, with the specified percentage being the mean of the percentage change for each group. We also performed a sensitivity analysis after excluding patients who underwent surgical resection. Variable adjustments for multivariable analyses were based on clinical relevance, considering the associations with microbiological cure, and the inclusion criterion was set at a significance level < 0.1.

For survival analysis, the patients were categorised into three groups: (1) cavity obliteration, (2) persistent cavity with size reduction, and (3) persistent cavity without size reduction. We compared the survival rates in the three groups using Kaplan–Meier curves and log-rank test.

A value of P < 0.05 for two-tailed tests was considered statistically significant. All analyses were conducted using R software version 4.3.0 (R Foundation for Statistical Computing, Vienna, Austria).

Results

Study population

A total of 261 patients with cavitary MAC-PD treated for ≥ 6 months were identified during the study period. After excluding 21 patients without chest CT scans at baseline, 90 patients lacking chest CT scans at treatment completion, and 14 patients with fewer than three available AFB culture results during treatment, 136 patients (median age, 62.6 [IQR, 55.6–71.4] years; 30.1% men) were included in the analysis (Table 1). Fifty-two-point two percent of patients were infected with M. avium, 46.3% with M. intracellulare, and 1.5% with M. chimaera. The median number of cavities was 1 (IQR, 1–3). The median transverse diameter and wall thickness of the largest cavity were 25.8 (IQR, 16.1–42.0) mm and 6.8 (IQR, 3.8–9.4) mm, respectively (Table 2). No significant differences were observed between patients infected with M. avium and those with M. intracellulare (Supplementary Material).Table 1 Characteristics of the study cohort.

Characteristics	Total (N = 136)	Microbiological cure (n = 74)	No cure (n = 62)	P-value	
Age, years (IQR)	62.6 (55.6–71.4)	58.5 (53.1–70.0)	65.2 (57.3–72.7)	0.011	
Men, n (%)	41 (30.1)	19 (25.7)	22 (35.5)	0.292	
Body mass index, kg/m2 (IQR) (n = 121)	20.8 (19.0–22.5)	20.9 (19.2–22.5)	20.8 (18.9–22.3)	0.736	
Erythrocyte sedimentation rate, mm/h (IQR) (n = 92)	33.5 (18.5–55.5)	28.5 (20.0–51.0)	40.0 (18.0–56.0)	0.401	
AFB smear positivity, n (%)	32 (23.5)	17 (23.0)	15 (24.2)	 > 0.99	
Mycobacterial species	0.151	
M. avium, n (%)	71 (52.2)	44 (59.5)	27 (43.5)		
M. intracellulare, n (%)	63 (46.3)	29 (39.2)	34 (54.8)	0.099	
M. chimaera, n (%)	2 (1.5)	1 (1.4)	1 (1.6)		
Macrolide resistance, n (%) (n = 134)	4 (3.0)	1 (1.4)	3 (4.9)	0.489	
Prior tuberculosis, n (%) (n = 84)	42 (50.0)	28 (58.3)	14 (38.9)	0.123	
Chronic obstructive pulmonary disease, n (%)	17 (12.5)	9 (12.2)	8 (12.9)	 > 0.99	
Bronchiectasis, n (%)	110 (80.9)	58 (78.4)	52 (83.9)	0.554	
Diabetes mellitus, n (%)	17 (12.5)	7 (9.5)	10 (16.1)	0.362	
Rheumatic disease, n (%)	4 (2.9)	3 (4.1)	1 (1.6)	0.742	
Smoking history, n (%) (n = 99)				0.162	
Never	67 (67.7)	42 (72.4)	25 (61.0)		
Past	30 (30.3)	16 (27.6)	14 (34.1)		
Current	2 (2.0)	0 (0.0)	2 (4.9)		
Immunocompromised or immunosuppressant use, n (%)	20 (14.7)	8 (10.8)	12 (19.4)	0.247	
Oral antibiotics					
Azithromycin, n (%)	101 (74.3)	50 (67.6)	51 (82.3)	0.079	
Clarithromycin, n (%)	41 (30.1)	26 (35.1)	15 (24.2)	0.231	
Ethambutol, n (%)	130 (95.6)	70 (94.6)	60 (96.8)	0.844	
Rifampicin, n (%)	91 (66.9)	53 (71.6)	38 (61.3)	0.275	
Clofazimine, n (%)	48 (35.3)	21 (28.4)	27 (43.5)	0.096	
Intravenous antibiotics	36 (26.5)	18 (24.3)	18 (29.0)	0.671	
Amikacin, n (%)	27 (19.9)	13 (17.6)	14 (22.6)	0.607	
Streptomycin, n (%)	9 (6.6)	5 (6.8)	4 (6.5)	 > 0.99	
Prescribed four drugs or more, n (%)	34 (25.0)	14 (18.9)	20 (32.3)	0.112	
Treatment duration, months (IQR)	20.0 (15.3–28.2)	19.5 (14.7–26.7)	21.0 (16.2–29.7)	0.511	
Surgical resection, n (%)	14 (10.3)	9 (12.2)	5 (8.1)	0.617	

Table 2 Cavity characteristics of the study cohort.

Cavity characteristics	Total (N = 136)	Microbiological cure (n = 74)	No cure (n = 62)	P-value	
Baseline	Size, mm (IQR)	25.8 (16.1–42.0)	24.1 (16.4–42.1)	26.2 (16.0–41.0)	0.751	
Thickness, mm (IQR)	6.8 (3.8–9.4)	6.2 (3.8–9.3)	7.0 (3.8–10.7)	0.471	
Number of cavities (IQR)	1 (1–3)	1 (1–3)	2 (1–4)	0.319	
Number of lobes infiltrated, (IQR)	1 (1–2)	1 (1–2)	1 (1–2)	0.461	
Bilaterality, n (%)	25 (18.4)	13 (17.6)	12 (19.4)	0.964	
Treatment completion	Size, mm (IQR) (n = 77)	24.4 (17.6–47.7)	21.8 (14.8–33.6)	27.7 (18.6–49.8)	0.155	
Thickness, mm (IQR) (n = 77)	5.7 (3.4–9.5)	4.5 (3.4–9.5)	6.1 (2.9–9.2)	0.500	
Number of cavities (IQR)	1 (0–3)	1 (0–2)	1 (1–3)	0.064	
Number of lobes infiltrated, (IQR)	1 (0–1)	1 (0–1)	1 (1–2)	0.048	
Bilaterality, n (%)	21 (15.4)	10 (13.5)	11 (17.7)	0.659	
Obliteration, n (%)	58 (42.6)	40 (54.1)	18 (29.0)	0.006	

After a median treatment duration of 20.0 (IQR, 15.3–28.2) months, 74 (54.4%) patients achieved microbiological cure. Patients who achieved microbiological cure were significantly younger than those who did not (P = 0.011). Other clinical characteristics including sex, BMI, macrolide resistance, prior tuberculosis, comorbidities, smoking history, and immunosuppressant use were comparable (Table 1). None of the patients in our study had HIV/AIDS. During a median follow-up period of 4.4 (IQR, 1.8–6.2) years, 23 patients died.

Cavity obliteration and treatment outcomes

No significant differences in baseline cavity characteristics, including size and wall thickness, were found between patients who achieved microbiological cure and those who did not (Table 2). Among the 136 patients, 58 (42.6%), including 16 patients with surgical resection, achieved obliteration of the largest cavity. The median time to obliteration was 13.3 (IQR, 10.7–19.7) months, and 12.9 (IQR, 10.7–16.5) months after excluding patients who underwent surgical resection. All but one patient maintained cavity obliteration until the end of treatment. Even in that patient, re-obliteration occurred by the completion of treatment. In the univariable analyses, cavity obliteration was associated with microbiological cure (odds ratio [OR], 2.88; 95% confidence interval [CI], 1.41–5.87; P = 0.004) (Table 3). Even after adjustment for relevant clinical factors, including age and M. intracellulare as causative species, cavity obliteration was independently associated with microbiological cure (adjusted OR, 2.41; 95% CI, 1.12–5.15; P = 0.024) (Table 3). The sensitivity analysis excluding 16 patients who underwent surgical resection showed similar results, and the significance was maintained (adjusted OR, 2.74; 95% CI, 1.18–6.37; P = 0.019) (Table 3).Table 3 Logistic regression between cavity characteristics and microbiological cure.

Characteristics	Microbiological cure	
Univariable	Multivariable	
OR (95% CI)	P	aOR (95% CI)	P	
Cavity obliteration*	2.88 (1.41–5.87)	0.004	2.41 (1.12–5.15)	0.024	
Cavity obliteration excluding patients who underwent resection*	3.24 (1.45–7.24)	0.004	2.74 (1.18–6.37)	0.019	
Transverse diameter#	Size reduction as continuous variable	1.03 (1.00–1.07)	0.059	1.04 (1.00–1.08)	0.053	
Size reduction surpassing MCID	3.54 (1.38–9.01)	0.008	4.41 (1.54–12.61)	0.006	
 ≥ 10% reduction in size	3.46 (1.35–8.85)	0.010	4.27 (1.52–12.03)	0.006	
 ≥ 10% increase in size	0.28 (0.10–0.82)	0.020	0.23 (0.07–0.72)	0.012	
Wall thickness$	Thickness reduction as continuous variable	1.03 (0.94–1.12)	0.53	1.05 (0.94–1.18)	0.36	
Thickness reduction surpassing MCID	1.09 (0.44–2.69)	0.86	1.09 (0.39–3.06)	0.87	
 ≥ 10% reduction in thickness	0.96 (0.39–2.37)	0.93	0.91 (0.34–2.44)	0.85	
 ≥ 10% increase in thickness	0.73 (0.28–1.90)	0.52	0.66 (0.23–1.91)	0.44	
*Adjusted for age and M. intracellulare as causative species in multivariable analyses.

#MCID was determined by the ROC method. Adjusted for baseline cavity transverse diameter and M. intracellulare as causative species in multivariable analyses.

$MCID was determined by the ROC method. Adjusted for baseline cavity wall thickness and M. intracellulare as causative species in multivariable analyses.

Changes in cavity size or wall thickness and treatment outcomes

Among patients with persistent cavities, the mean change in transverse diameter of the largest cavity was − 1.24 [standard deviation (SD), ± 15.04] mm following treatment. The mean change in cavity diameter differed significantly by microbiological cure status [cured: mean, − 5.0 mm (− 12%); uncured: mean, + 1.7 mm (+ 11%); P = 0.035]. Decrease in cavity diameter, when considered as a continuous variable, was not significantly associated with microbiological cure (adjusted OR, 1.04; 95% CI, 1.00–1.08; P = 0.053) (Table 3), but a trend was suggested. Reduction in cavity size surpassing the MCIDs (ROC method, − 1.8 mm; SEM method, 2.1 mm) was significantly associated with microbiological cure (Table 3). Furthermore, ≥ 10% reduction in size was associated with microbiological cure (adjusted OR, 4.27; 95% CI, 1.52–12.03; P = 0.006), while ≥ 10% increase in size was associated with unfavourable outcome (adjusted OR, 0.23; 95% CI, 0.07–0.72; P = 0.012). Size reduction at 6 and 12 months was maintained through treatment completion in 81.6% (31/38) and 80% (24/30) of patients, respectively.

The mean change in wall thickness of the largest cavity was − 1.54 (SD, ± 5.51) mm following treatment. The mean change in wall thickness did not differ significantly between patients who achieved microbiological cure and those who did not (cured: mean ± SD, − 1.98 ± 4.54 mm; uncured: mean ± SD, − 1.20 ± 6.18 mm; P = 0.73). Regardless of reduction or increase, a change in wall thickness was not associated with microbiological cure (Table 3).

Cavity obliteration or change in cavity size and survival

When Kaplan–Meier curves stratified by cavity status were plotted, the survival curves diverged significantly (P < 0.001). The 5-year mortality rates in patients with cavity obliteration, persistent cavity with size reduction, and persistent cavity without size reduction were 95.6% (95% CI, 89.8%–100%), 72.1% (95% CI, 56.7%–91.6%), and 65.3% (95% CI, 49.1%–87.0%), respectively (Fig. 2).Fig. 2 Cavity obliteration or size changes and survival. Kaplan–Meier survival curves of patients with cavity obliteration (black), persistent cavity with size reduction (red), and persistent cavity without size reduction (blue). The 5-year mortality rates in patients with cavity obliteration, persistent cavity with size reduction, and persistent cavity without size reduction were 95.6% (95% CI, 89.8–100%), 72.1% (95% CI, 56.7–91.6%), and 65.3% (95% CI, 49.1–87.0%), respectively.

Discussion

In this cohort study involving 136 patients with cavitary MAC-PD, we examined the associations of changes in cavity characteristics with treatment outcomes. Cavity obliteration, characterised by closure or complete removal of abnormal air-filled spaces, was significantly associated with microbiological cure. Meanwhile, patients with a reduction in cavity size despite cavity persistence had a higher likelihood of achieving microbiological cure. Patients with cavity obliteration exhibited the longest survival, followed by those with reduced cavity size despite cavity persistence and those with persistent cavity without size reduction.

Our findings have clinical significance because, to date, limited data have been available regarding the dynamic changes in cavities during treatment and their clinical implications. Previous studies have primarily focused on the radiological characteristics, including cavitation, at the start of treatment3,27. The lack of longitudinal data has meant that understanding of how cavities evolve during treatment and the potential clinical implications of the changes have remained unclear. In the present study, a substantial proportion (42.6%) of the patients experienced cavity obliteration after treatment. Among the remaining patients with persistent cavities, more than half (57.7%) experienced a reduction in size. In addition, cavity obliteration and shrinkage were associated with microbiological cure and, eventually, survival. Our results demonstrate that cavities do not remain static but rather change dynamically with treatment, and that the changes are closely related to microbiological and long-term outcomes.

The cavities in MAC-PD represent the frontline for encounters between host immunity and pathogens, similar to the case for pulmonary tuberculosis8. Consequently, cavity obliteration signifies that the host immune system has achieved successful containment and suppression of the pathogen, coupled with antibiotic treatment. This achievement mitigates inflammation and diminishes the risk of additional bacilli dissemination. The median time to cavitary obliteration was approximately 13 months in our study. Once cavity obliteration was achieved, it was highly unlikely to aggravate afterwards. Among patients with non-obliterated cavities, 80% of patients whose cavity size was reduced at 12 months of treatment maintained this trend until treatment completion. However, if cavity was enlarged after 12 months of treatment, the chance of further improvement was significantly rare. These findings suggest that obtaining CT scans around one year of treatment might be a reasonable option. Additional CT scans may be unnecessary for patients whose cavities are obliterated or reduced in size at 12 months. Conversely, additional interventions, such as surgical removal of the cavity, should be discussed with patients whose cavities are unresponsive to more than 12 months of antibiotic treatment28.

In the present study, change in wall thickness was not associated with treatment response. Because thicker cavity walls have been linked to higher degrees of AFB smear positivity in pulmonary tuberculosis29, we hypothesised that wall thickness may indirectly represent the mycobacterial burden. In our analysis, wall thickness decreased with treatment regardless of the microbiological outcome, suggesting its responsiveness to treatment. Our findings further demonstrated that, rather than the inner wall thickness composed of necrotic cellular debris and cholesterols, the transverse diameter of cavities reflecting the entire granulomatous inflammation constructed by the host defence mechanism may be a more suitable indicator of treatment response.

Our finding that cavity obliteration following treatment is associated with microbiological cure suggests that the cavities in MAC-PD reflect the overall bacillary burden, similar to the case for pulmonary tuberculosis8. Based on our previous observation that microbiological cure is associated with long-term survival irrespective of cavity presence at treatment completion17, the prolonged survival observed in patients experiencing cavity obliteration may be attributed to a reduction in the mycobacterial burden. Hence, it is reasonable to assume that cavity changes can be a surrogate measure for the mycobacterial burden rather than an independent prognostic factor for survival. In this context, our findings demonstrate that cavity changes can serve as an additional proxy indicator for evaluation of treatment response, complementing mycobacterial culture results. Assessment of changes in cavity size during treatment could be especially useful when evaluating the treatment response in patients who cannot expectorate sputum20.

The strength of this study lies in the utilisation of longitudinal CT scan data in a cohort of patients with cavitary MAC-PD to shed light on the changes in cavity characteristics after treatment associated with microbiological response and long-term survival. However, a major limitation is that a substantial number of patients were excluded from the analysis due to the unavailability of CT scans at treatment completion. Furthermore, few (1.5%) patients were infected with M. chimaera, which is relatively rare in Korean cohorts30,31. Since virulence and clinical course can vary by species32, our findings may have limited applicability in regions where the prevalence of causative species differs. We also included patients who underwent surgical resection during antibiotic treatment to provide a more comprehensive view of current treatment options and outcomes. However, the characteristics of these patients may differ from those who received only medical treatment, such as having more localized disease or being less frail. Nonetheless, results were maintained even after excluding surgical patients in the sensitivity analysis.

In conclusion, cavity obliteration or size reduction at the end of treatment in patients with MAC-PD is associated with microbiological cure and reduced mortality. Cavity changes have the potential to serve as a surrogate marker for treatment response supplementing microbiological culture data.

Supplementary Information

Supplementary Tables.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-024-71971-6.

Author contributions

J-YK: Conceptualization, Methodology, Investigation, Data curation, Formal analysis, Visualization, Writing-original draft, Writing-review & editing; JB: Methodology, Investigation, Data curation, Writing-review & editing; KH: Data curation, Writing-review & editing; IL: Data curation, Writing-review & editing; H-JP: Data curation, Writing-review & editing; SYK: Data curation, Writing-review & editing; K-EL: Data curation, Writing-review & editing; YHA: Data curation, Writing-review & editing; SMY: Data curation, Writing-review & editing; NK: Data curation, Methodology, Resources, Writing-review & editing; J-JY: Conceptualization, Data curation, Methodology, Project administration, Resources, Supervision, Visualization, Writing-review & editing.

Data availability

The datasets used in the current study are available from the corresponding author on reasonable request after Institutional Review Board approval.

Competing interests

The authors declare no competing interests.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Daley CL Iaccarino JM Lange C Cambau E Wallace RJ Jr Andrejak C Bottger EC Brozek J Griffith DE Guglielmetti L Huitt GA Knight SL Leitman P Marras TK Olivier KN Santin M Stout JE Tortoli E van Ingen J Wagner D Winthrop KL Treatment of nontuberculous mycobacterial pulmonary disease: An official ATS/ERS/ESCMID/IDSA clinical practice guideline Clin. Infect. Dis. 2020 71 e1 e36 10.1093/cid/ciaa241 32628747
Daley, C. L. et al. Treatment of nontuberculous mycobacterial pulmonary disease: An official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin. Infect. Dis. 71, e1–e36 (2020).32628747 10.1093/cid/ciaa241
2. Griffith DE Aksamit T Brown-Elliott BA Catanzaro A Daley C Gordin F Holland SM Horsburgh R Huitt G Iademarco MF Iseman M Olivier K Ruoss S von Reyn CF Wallace RJ Jr Winthrop K An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases Am. J. Respir. Crit. Care Med. 2007 175 367 416 10.1164/rccm.200604-571ST 17277290
Griffith, D. E. et al. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 175, 367–416 (2007).17277290 10.1164/rccm.200604-571ST
3. Koh W-J Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype Eur. Respir. J. 2017 50 3 1602503 10.1183/13993003.02503-2016 28954780
Koh, W.-J. et al. Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. Eur. Respir. J. 50(3), 1602503 (2017).28954780 10.1183/13993003.02503-2016
4. Jhun BW Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a 15-year follow-up study Eur. Respir. J. 2022 55 1 1900798 10.1183/13993003.00798-2019
Jhun, B. W. et al. Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a 15-year follow-up study. Eur. Respir. J. 55(1), 1900798 (2022).10.1183/13993003.00798-2019
5. Gadkowski LB Stout JE Cavitary pulmonary disease Clin. Microbiol. Rev. 2008 21 305 333 10.1128/CMR.00060-07 18400799
Gadkowski, L. B. & Stout, J. E. Cavitary pulmonary disease. Clin. Microbiol. Rev. 21, 305–333 (2008).18400799 10.1128/CMR.00060-07
6. Ihms EA Urbanowski ME Bishai WR Diverse cavity types and evidence that mechanical action on the necrotic granuloma drives tuberculous cavitation Am. J. Pathol. 2018 188 1666 1675 10.1016/j.ajpath.2018.04.006 29753789
Ihms, E. A., Urbanowski, M. E. & Bishai, W. R. Diverse cavity types and evidence that mechanical action on the necrotic granuloma drives tuberculous cavitation. Am. J. Pathol. 188, 1666–1675 (2018).29753789 10.1016/j.ajpath.2018.04.006
7. Hansell DM Bankier AA MacMahon H McLoud TC Müller NL Remy J Fleischner society: Glossary of terms for thoracic imaging Radiology 2008 246 697 722 10.1148/radiol.2462070712 18195376
Hansell, D. M. et al. Fleischner society: Glossary of terms for thoracic imaging. Radiology 246, 697–722 (2008).18195376 10.1148/radiol.2462070712
8. Urbanowski ME Ordonez AA Ruiz-Bedoya CA Jain SK Bishai WR Cavitary tuberculosis: The gateway of disease transmission Lancet Infect. Dis. 2020 20 e117 e128 10.1016/S1473-3099(20)30148-1 32482293
Urbanowski, M. E., Ordonez, A. A., Ruiz-Bedoya, C. A., Jain, S. K. & Bishai, W. R. Cavitary tuberculosis: The gateway of disease transmission. Lancet Infect. Dis. 20, e117–e128 (2020).32482293 10.1016/S1473-3099(20)30148-1
9. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am. J. Respir. Crit. Care Med. 156, S1–25 (1997).
10. Lee Y Song JW Chae EJ Lee HJ Lee CW Do KH Seo JB Kim MY Lee JS Song KS Shim TS CT findings of pulmonary non-tuberculous mycobacterial infection in non-AIDS immunocompromised patients: A case-controlled comparison with immunocompetent patients Br. J. Radiol. 2013 86 20120209 10.1259/bjr.20120209 23440166
Lee, Y. et al. CT findings of pulmonary non-tuberculous mycobacterial infection in non-AIDS immunocompromised patients: A case-controlled comparison with immunocompetent patients. Br. J. Radiol. 86, 20120209 (2013).23440166 10.1259/bjr.20120209
11. Henkle E Winthrop KL Nontuberculous mycobacteria infections in immunosuppressed hosts Clin. Chest Med. 2015 36 91 99 10.1016/j.ccm.2014.11.002 25676522
Henkle, E. & Winthrop, K. L. Nontuberculous mycobacteria infections in immunosuppressed hosts. Clin. Chest Med. 36, 91–99 (2015).25676522 10.1016/j.ccm.2014.11.002
12. Kim SJ Yoon SH Choi SM Lee J Lee CH Han SK Yim JJ Characteristics associated with progression in patients with of nontuberculous mycobacterial lung disease : A prospective cohort study BMC Pulm. Med. 2017 17 5 10.1186/s12890-016-0349-3 28056937
Kim, S. J. et al. Characteristics associated with progression in patients with of nontuberculous mycobacterial lung disease : A prospective cohort study. BMC Pulm. Med. 17, 5 (2017).28056937 10.1186/s12890-016-0349-3
13. Kim HJ Kwak N Hong H Kang N Im Y Jhun BW Yim JJ BACES score for predicting mortality in nontuberculous mycobacterial pulmonary disease Am. J. Respir. Crit. Care Med. 2021 203 230 236 10.1164/rccm.202004-1418OC 32721164
Kim, H. J. et al. BACES score for predicting mortality in nontuberculous mycobacterial pulmonary disease. Am. J. Respir. Crit. Care Med. 203, 230–236 (2021).32721164 10.1164/rccm.202004-1418OC
14. Ogawa T Asakura T Suzuki S Okamori S Kusumoto T Sato Y Namkoong H Kamata H Ishii M Fukunaga K Hasegawa N Longitudinal validity and prognostic significance of the St George's Respiratory Questionnaire in Mycobacterium avium complex pulmonary disease Respir. Med. 2021 185 106515 10.1016/j.rmed.2021.106515 34175804
Ogawa, T. et al. Longitudinal validity and prognostic significance of the St George’s Respiratory Questionnaire in Mycobacterium avium complex pulmonary disease. Respir. Med. 185, 106515 (2021).34175804 10.1016/j.rmed.2021.106515
15. CLSI. Laboratory Detection and Identification of Mycobacteria (2nd ed.) CLSI guideline M48 (Clinical and Laboratory Standards Institute, 2018).
16. Kim JY Park S Park IK Kang CH Kim YT Koh J Yim JJ Kwak N Outcomes of adjunctive surgery for nontuberculous mycobacterial pulmonary disease BMC Pulm. Med. 2021 21 312 10.1186/s12890-021-01679-0 34615499
Kim, J. Y. et al. Outcomes of adjunctive surgery for nontuberculous mycobacterial pulmonary disease. BMC Pulm. Med. 21, 312 (2021).34615499 10.1186/s12890-021-01679-0
17. Kim JY Park J Choi Y Kim TS Kwak N Yim JJ Microbiological cure at treatment completion is associated with longer survival in patients with Mycobacterium avium complex pulmonary disease Chest 2023 164 1108 1114 10.1016/j.chest.2023.06.015 37423256
Kim, J. Y. et al. Microbiological cure at treatment completion is associated with longer survival in patients with Mycobacterium avium complex pulmonary disease. Chest 164, 1108–1114 (2023).37423256 10.1016/j.chest.2023.06.015
18. Kim JY Choi Y Park J Goo JM Kim TS Seong MW Kwak N Yim JJ Impact of treatment on long-term survival of patients with Mycobacterium avium complex pulmonary disease Clin. Infect. Dis. 2023 77 120 126 10.1093/cid/ciad108 36861203
Kim, J. Y. et al. Impact of treatment on long-term survival of patients with Mycobacterium avium complex pulmonary disease. Clin. Infect. Dis. 77, 120–126 (2023).36861203 10.1093/cid/ciad108
19. Kim JY Lee S Park H Kim HJ Lee HW Lee JH Yim JJ Kwak N Yoon SH Post-treatment radiographic severity and mortality in Mycobacterium avium complex pulmonary disease Ann. Am. Thorac. Soc. 2024 21 235 242 10.1513/AnnalsATS.202305-407OC 37788406
Kim, J. Y. et al. Post-treatment radiographic severity and mortality in Mycobacterium avium complex pulmonary disease. Ann. Am. Thorac. Soc. 21, 235–242 (2024).37788406 10.1513/AnnalsATS.202305-407OC
20. van Ingen J Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement Eur. Respir. J. 2018 51 3 1800170 10.1183/13993003.00170-2018 29567726
van Ingen, J. et al. Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. Eur. Respir. J. 51(3), 1800170 (2018).29567726 10.1183/13993003.00170-2018
21. Cheon H Comparison of CT findings of between MDR-TB and XDR-TB: A propensity score matching study Imaging Med. 2017 9 125 129
Cheon, H. Comparison of CT findings of between MDR-TB and XDR-TB: A propensity score matching study. Imaging Med. 9, 125–129 (2017).
22. Kang HR Clinical implications of size of cavities in patients with nontuberculous mycobacterial pulmonary disease: A single-center cohort study Open Forum Infect. Dis. 2021 8 3 ofab087 10.1093/ofid/ofab087 33796599
Kang, H. R. et al. Clinical implications of size of cavities in patients with nontuberculous mycobacterial pulmonary disease: A single-center cohort study. Open Forum Infect. Dis. 8(3), ofab087 (2021).33796599 10.1093/ofid/ofab087
23. Kim HS Lee KS Koh WJ Jeon K Lee EJ Kang H Ahn J Serial CT findings of Mycobacterium massiliense pulmonary disease compared with Mycobacterium abscessus disease after treatment with antibiotic therapy Radiology 2012 263 260 270 10.1148/radiol.12111374 22371609
Kim, H. S. et al. Serial CT findings of Mycobacterium massiliense pulmonary disease compared with Mycobacterium abscessus disease after treatment with antibiotic therapy. Radiology 263, 260–270 (2012).22371609 10.1148/radiol.12111374
24. Tokugawa H The cavity healing in pulmonary tuberculosis Keio J. Med. 1955 4 65 92 10.2302/kjm.4.65
Tokugawa, H. The cavity healing in pulmonary tuberculosis. Keio J. Med. 4, 65–92 (1955).10.2302/kjm.4.65
25. Tahira D Alonso C-L Anila Q Mark P Bradley CJ Niveditha D Dena Z Meha B Xuejing J Romina B-P Olivia U Farid F Stefan S Hector P-H Robin WMV Hsiaomin H Yamna R Reed S Lyubov L Donald LP Shanil E Toshi F Gihad N Holger JS Mohit B Lehana T Gordon HG Evaluating the credibility of anchor based estimates of minimal important differences for patient reported outcomes: Instrument development and reliability study BMJ 2020 369 m1714 32499297
Tahira, D. et al. Evaluating the credibility of anchor based estimates of minimal important differences for patient reported outcomes: Instrument development and reliability study. BMJ 369, m1714 (2020).32499297
26. Terwee CB Roorda LD Dekker J Bierma-Zeinstra SM Peat G Jordan KP Croft P de Vet HC Mind the MIC: Large variation among populations and methods J. Clin. Epidemiol. 2010 63 524 534 10.1016/j.jclinepi.2009.08.010 19926446
Terwee, C. B. et al. Mind the MIC: Large variation among populations and methods. J. Clin. Epidemiol. 63, 524–534 (2010).19926446 10.1016/j.jclinepi.2009.08.010
27. Rawson TM Abbara A Kranzer K Ritchie A Milburn J Brown T Adeboyeku D Buckley J Davidson RN Berry M Kon OM John L Factors which influence treatment initiation for pulmonary non-tuberculous mycobacterium infection in HIV negative patients; A multicentre observational study Respir. Med. 2016 120 101 108 10.1016/j.rmed.2016.10.001 27817806
Rawson, T. M. et al. Factors which influence treatment initiation for pulmonary non-tuberculous mycobacterium infection in HIV negative patients; A multicentre observational study. Respir. Med. 120, 101–108 (2016).27817806 10.1016/j.rmed.2016.10.001
28. Kim JY Lee HW Yim JJ Kwak N Outcomes of adjunctive surgery in patients with nontuberculous mycobacterial pulmonary disease: A systematic review and meta-analysis Chest 2023 163 763 777 10.1016/j.chest.2022.09.037 36208713
Kim, J. Y., Lee, H. W., Yim, J. J. & Kwak, N. Outcomes of adjunctive surgery in patients with nontuberculous mycobacterial pulmonary disease: A systematic review and meta-analysis. Chest 163, 763–777 (2023).36208713 10.1016/j.chest.2022.09.037
29. Ors F Deniz O Bozlar U Gumus S Tasar M Tozkoparan E Tayfun C Bilgic H Grant BJ High-resolution CT findings in patients with pulmonary tuberculosis: Correlation with the degree of smear positivity J. Thorac. Imaging 2007 22 154 159 10.1097/01.rti.0000213590.29472.ce 17527119
Ors, F. et al. High-resolution CT findings in patients with pulmonary tuberculosis: Correlation with the degree of smear positivity. J. Thorac. Imaging 22, 154–159 (2007).17527119 10.1097/01.rti.0000213590.29472.ce
30. Kim MJ Kim KM Shin JI Ha JH Lee DH Choi JG Park JS Byun JH Yoo JW Eum S Jung M Baik SC Lee WK Kang HL Shin MK Identification of nontuberculous mycobacteria in patients with pulmonary diseases in Gyeongnam, Korea, using multiplex PCR and multigene sequence-based analysis Can. J. Infect. Dis. Med. Microbiol. 2021 2021 8844306 10.1155/2021/8844306 33688383
Kim, M. J. et al. Identification of nontuberculous mycobacteria in patients with pulmonary diseases in Gyeongnam, Korea, using multiplex PCR and multigene sequence-based analysis. Can. J. Infect. Dis. Med. Microbiol. 2021, 8844306 (2021).33688383 10.1155/2021/8844306
31. Kim SY Shin SH Moon SM Yang B Kim H Kwon OJ Huh HJ Ki CS Lee NY Shin SJ Koh WJ Distribution and clinical significance of Mycobacterium avium complex species isolated from respiratory specimens Diagn. Microbiol. Infect. Dis. 2017 88 125 137 10.1016/j.diagmicrobio.2017.02.017 28291631
Kim, S. Y. et al. Distribution and clinical significance of Mycobacterium avium complex species isolated from respiratory specimens. Diagn. Microbiol. Infect. Dis. 88, 125–137 (2017).28291631 10.1016/j.diagmicrobio.2017.02.017
32. Boyle DP Zembower TR Reddy S Qi C Comparison of clinical features, virulence, and relapse among Mycobacterium avium complex species Am. J. Respir. Crit. Care Med. 2015 191 1310 1317 10.1164/rccm.201501-0067OC 25835090
Boyle, D. P., Zembower, T. R., Reddy, S. & Qi, C. Comparison of clinical features, virulence, and relapse among Mycobacterium avium complex species. Am. J. Respir. Crit. Care Med. 191, 1310–1317 (2015).25835090 10.1164/rccm.201501-0067OC
